viewHeat Biologics

Heat Biologics expands its Phase 2 trial in combination with Merck’s Keytruda to treat non-small cell lung cancer

Heat Biologics Inc (NASDAQ:PHTBX) Founder & CEO Jeffrey Wolf tells Proactive Investors the company, which is developing therapies designed to activate a patient's immune system against cancer, has dosed its first patient in its Phase 2 trial with its drug HS-110 in combination with Merck & Co's (NYSE:MRK) Keytruda to treat patients with advanced non-small cell lung cancer.

Wolf says in addition to this milestone, the North Carolina-based company will has been selected to deliver an oral presentation summarizing new data from the company's Phase 2 trial of HS-110 in combination with Bristol-Myers Squibb's (NYSE:BMY) drug Opdivo.

Quick facts: Heat Biologics

Price: 0.3125 USD

Market: NASDAQ
Market Cap: $11.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Heat Biologics named herein, including the promotion by the Company of Heat Biologics in any Content on the Site, the Company receives from...



Full interview: Heat Biologics doses its first patient in its Phase 1 trial...

Heat Biologics, Inc. (NASDAQ:HTBX) CEO Jeff Wolf tells Proactive the North Carolina-based biotechnology company has dosed its first patient in its Phase 1 trial of its drug HS-130 in combination with HS-110. Wolf says the combinational trial is meant to treat patients with advanced solid cancer...

on 12/17/2019

2 min read